TL;DR - Stryker (NYSE: SYK) Q2 2026 adjusted EPS USD 3.69 (+17.9% YoY), beat consensus of USD 3.49 by 5.7% - Revenue USD 6.6B (+9.4% YoY, organic +9.0%), narrowly beat the USD 6.58B estimate - Shares fell ~5.1% pre-market to USD 330.45 (prior close USD 348.04) despite the beat — investors weigh H2 cyber remediation costs - FY2026 guidance narrowed: adjusted EPS USD 14.95–USD 15.10, organic growth 8.3%–9.3%
Part A: What Was Reported
Stryker Corporation (NYSE: SYK), a medical technology company with a market capitalization of approximately USD 133 billion, reported its Q2 2026 results on July 30, 2026. The company beat analyst estimates on both the top and bottom lines but provided guidance that left investors cautious about the second half.
Q2 2026 Key Metrics
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Net Sales | USD 6.6B | USD 6.03B | +9.4% |
| Organic Sales Growth | — | — | +9.0% |
| Adjusted EPS | USD 3.69 | USD 3.13 | +17.9% |
| GAAP EPS | USD 3.30 | USD 2.29 | +44.1% |
| Adjusted Operating Margin | 27.4% | 25.7% | +170 bps |
Segment Breakdown
| Segment | Q2 2026 Revenue | YoY Growth |
|---|---|---|
| MedSurg & Neurotechnology | USD 3.625B | +9.7% |
| Orthopaedics | USD 2.964B | +9.1% |
MedSurg & Neurotechnology — Stryker's largest segment — missed the analyst estimate of approximately USD 3.72B, a detail the market focused on despite the overall revenue beat.
